MET Exon 14 Skipping Mutations in Non–Small Cell Lung Cancer

Drs Joshua M. Bauml and Lyudmila A. Bazhenova describe what is understood regarding the behavior of MET exon 14 skipping mutations in non–small cell lung cancer and remark on their prevalence among specific patient populations.

Drs Joshua M. Bauml and Benjamin Levy react to the development of novel therapies that specifically target MET exon 14 skipping mutations in non–small cell lung cancer.

Recommendations for using next-generations sequencing panels as well as liquid biopsies to help identify MET exon 14 skipping mutations and other oncogenic drivers in patients with non–small cell lung cancer.

Discussion on the FDA approval of capmatinib, a MET inhibitor, as treatment for patients with MET exon 14-mutated non–small cell lung cancer based on data demonstrated by the GEOMETRY mono-1 study.

Implications for treating patients with non–small cell lung cancer who harbor MET exon 14 skipping mutations with tepotinib, a MET inhibitor, based on data revealed by the VISION trial.

The significance of using MET inhibitors to manage patients who have MET exon 14 skipping mutations in non–small cell lung cancer with CNS (central nervous system) involvement.

A comparison between the MET inhibitors available to treat MET exon 14 skipping mutations in non–small cell lung cancer and factors that should be considered when selecting a type 1 or type 2 MET-directed therapy.

Drs Joshua M. Bauml and Benjamin Levy highlight more common adverse events associated with MET inhibitors used to treat MET exon 14 skipping mutations in non–small cell lung cancer and share strategies to help manage patients on therapy.

The rationale for using MET inhibitors as first-line therapy for patients with non–small cell lung cancer who harbor MET exon 14 skipping mutations and considerations for sequencing later lines of therapy based on what is known to date about mechanisms of resistance to MET inhibitors.

Healthcare professionals who manage patients with non–small cell lung cancer comment on their current experience using MET inhibitors as treatment for patients who harbor MET exon 14 skipping mutations and highlight strategies under investigation that will hopefully address current gaps in therapy.